• Publications
  • Influence
A Clinical Service in the UK to Predict Fetal Rh (Rhesus) D Blood Group Using Free Fetal DNA in Maternal Plasma
Abstract: Antenatal determination of fetal blood group is important in pregnancies with a significant risk of hemolytic anemia due to maternal alloimmunization. The International Blood GroupExpand
  • 126
  • 7
Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study
Objectives To assess the accuracy of fetal RHD genotyping using cell-free fetal DNA in maternal plasma at different gestational ages. Design A prospective multicentre cohort study. Setting SevenExpand
  • 70
  • 7
  • PDF
Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects
Fetuses of women with alloantibodies to RhD (D) are at risk from hemolytic disease of the fetus and newborn, but only if the fetal red cells are D‐positive. In such pregnancies, it is beneficial toExpand
  • 145
  • 6
Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study
Objectives To assess the feasibility of applying a high throughput method, with an automated robotic technique, for predicting fetal RhD phenotype from fetal DNA in the plasma of RhD negativeExpand
  • 168
  • 6
  • PDF
Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell‐free fetal DNA in maternal plasma
BACKGROUND: When a pregnant woman has an antibody with the potential to cause hemolytic disease of the fetus and newborn, it is beneficial to determine whether her fetus has the corresponding antigenExpand
  • 109
  • 6
Non‐invasive prenatal determination of fetal sex: translating research into clinical practice
Hill M, Finning K, Martin P, Hogg J, Meaney C, Norbury G, Daniels G, Chitty LS. Non‐invasive prenatal determination of fetal sex: translating research into clinical practice.
  • 134
  • 5
  • PDF
Fetal RHD Genotyping in Maternal Plasma at 11–13 Weeks of Gestation
Objective: To examine the feasibility of fetal RHD genotyping at 11–13 weeks’ gestation from analysis of circulating cell-free fetal DNA (ccffDNA) in the plasma of RhD negative pregnant women using aExpand
  • 45
  • 5
  • PDF
Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
The most important application of blood group genotyping by molecular genetics is the prediction of fetal RhD phenotype in pregnant women with anti-D, in order to assess the risk of haemolyticExpand
  • 21
  • 5
Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service
BACKGROUND : Invasive procedures to obtain fetal DNA for prenatal blood grouping present a risk to the fetus. During pregnancy, cell‐free fetal DNA is present in maternal blood. The detection of RHDExpand
  • 328
  • 4